The biological plausibility remains elusive given the mechanism of action of the drugs and brings into question whether it is possible for any serotonin agonist to lead to SS via displacement of endogenous serotonin and resulting accessibility to 5-HT1A or 5-HT2A receptors. Here, HTR1A is linked to synovial sarcoma.